CA2433794A1 - Uses for polycationic compounds as vaccine adjuvants - Google Patents
Uses for polycationic compounds as vaccine adjuvants Download PDFInfo
- Publication number
- CA2433794A1 CA2433794A1 CA002433794A CA2433794A CA2433794A1 CA 2433794 A1 CA2433794 A1 CA 2433794A1 CA 002433794 A CA002433794 A CA 002433794A CA 2433794 A CA2433794 A CA 2433794A CA 2433794 A1 CA2433794 A1 CA 2433794A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- cpg
- use according
- poly
- polycationic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 63
- 239000012646 vaccine adjuvant Substances 0.000 title description 2
- 229940124931 vaccine adjuvant Drugs 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000000427 antigen Substances 0.000 claims description 63
- 108091007433 antigens Proteins 0.000 claims description 63
- 102000036639 antigens Human genes 0.000 claims description 63
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 56
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 13
- 238000009826 distribution Methods 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000002163 immunogen Effects 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 108010011110 polyarginine Proteins 0.000 claims description 3
- 229930010555 Inosine Natural products 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 24
- 238000001727 in vivo Methods 0.000 abstract description 11
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 49
- 238000002347 injection Methods 0.000 description 38
- 239000007924 injection Substances 0.000 description 38
- 239000000126 substance Substances 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000009885 systemic effect Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 15
- 108090001005 Interleukin-6 Proteins 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108010007004 cathelin Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- 230000028993 immune response Effects 0.000 description 8
- 230000003308 immunostimulating effect Effects 0.000 description 8
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 230000005923 long-lasting effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007108 local immune response Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 108010084754 Tuftsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 108060001132 cathelicidin Proteins 0.000 description 2
- 102000014509 cathelicidin Human genes 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920002851 polycationic polymer Polymers 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 229940035670 tuftsin Drugs 0.000 description 2
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- ZYECOAILUNWEAL-NUDFZHEQSA-N (4z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-n-(3-nitrophenyl)-3-oxonaphthalene-2-carboxamide Chemical compound COC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1N\N=C(C1=CC=CC=C1C=1)/C(=O)C=1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 ZYECOAILUNWEAL-NUDFZHEQSA-N 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- OTAMFXXAGYBAQL-YXMSTPNBSA-N Kentsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O OTAMFXXAGYBAQL-YXMSTPNBSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940046545 animal allergen extract Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 108010043612 kentsin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2001/000087 WO2001054720A1 (en) | 2000-01-28 | 2001-01-05 | Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants |
| EPPCT/EP01/00087 | 2001-01-05 | ||
| ATA672/2001 | 2001-04-25 | ||
| AT6722001 | 2001-04-25 | ||
| PCT/EP2002/000062 WO2002053184A2 (en) | 2001-01-05 | 2002-01-07 | Uses for polycationic compounds as vaccine adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2433794A1 true CA2433794A1 (en) | 2002-07-11 |
Family
ID=25608382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002433794A Abandoned CA2433794A1 (en) | 2001-01-05 | 2002-01-07 | Uses for polycationic compounds as vaccine adjuvants |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1347775B1 (enExample) |
| JP (1) | JP2004519452A (enExample) |
| CA (1) | CA2433794A1 (enExample) |
| WO (1) | WO2002053184A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1347775B1 (en) | 2001-01-05 | 2016-11-30 | Valneva Austria GmbH | Uses for polycationic compounds as vaccine adjuvants |
| EP1608402B1 (en) * | 2003-03-24 | 2010-10-20 | Intercell AG | Improved vaccines |
| WO2011101465A1 (en) | 2010-02-19 | 2011-08-25 | Intercell Ag | Ic31 nanoparticles |
| KR101586200B1 (ko) * | 2014-12-31 | 2016-01-18 | 성균관대학교산학협력단 | 면역자극 조성물, 이의 제조 방법, 및 이를 포함하는 면역요법 조성물 |
| US20230210763A1 (en) * | 2019-09-19 | 2023-07-06 | Amw Gmbh | Extruded depot form for controlled active substance release |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB744988A (en) * | 1952-01-31 | 1956-02-15 | Allen & Hanburys Ltd | Improvements in preparations of insulin |
| GB8921470D0 (en) * | 1989-09-22 | 1989-11-08 | Peptide Technology Ltd | Vaccines |
| AU653771B2 (en) * | 1991-01-03 | 1994-10-13 | Alkermes Controlled Therapeutics, Inc. | Stabilization of proteins by cationic biopolymers |
| CO4600681A1 (es) * | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| DE60003151T2 (de) * | 1999-01-13 | 2004-04-08 | Johns Hopkins University School Of Medicine | Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen |
| PL203951B1 (pl) * | 1999-04-19 | 2009-11-30 | Smithkline Beecham Biolog | Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie |
| AT408721B (de) * | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| HU228264B1 (en) * | 2000-06-08 | 2013-02-28 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| EP1347775B1 (en) | 2001-01-05 | 2016-11-30 | Valneva Austria GmbH | Uses for polycationic compounds as vaccine adjuvants |
-
2002
- 2002-01-07 EP EP02700194.0A patent/EP1347775B1/en not_active Expired - Lifetime
- 2002-01-07 JP JP2002554133A patent/JP2004519452A/ja active Pending
- 2002-01-07 WO PCT/EP2002/000062 patent/WO2002053184A2/en not_active Ceased
- 2002-01-07 CA CA002433794A patent/CA2433794A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004519452A (ja) | 2004-07-02 |
| EP1347775A2 (en) | 2003-10-01 |
| EP1347775B1 (en) | 2016-11-30 |
| WO2002053184A3 (en) | 2002-09-19 |
| WO2002053184A2 (en) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002212326B2 (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties | |
| US20080025996A1 (en) | Methods and Compositions Comprising Polycationic Compounds | |
| AU784403B2 (en) | Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants | |
| RU2293573C2 (ru) | Иммуностимулирующие олигодезоксинуклеотиды | |
| AU2002212326A1 (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties | |
| JP2008222721A6 (ja) | ワクチン組成物 | |
| JP2006521321A (ja) | 免疫応答を促進するためのミョウバンおよびＴｈ１免疫応答誘起アジュバントの使用 | |
| EP1347775B1 (en) | Uses for polycationic compounds as vaccine adjuvants | |
| EP1347776A2 (en) | Anti-inflammatory use of polycationic compounds | |
| US20040081655A1 (en) | Methods and compositions comprising polycationic compounds | |
| AU2002233302A1 (en) | Uses for polycationic compounds as vaccine adjuvants | |
| AU2002235820A1 (en) | Anti-inflammatory use of polycationic compounds | |
| HK1055899B (en) | Vaccine composition comprising an antigen and a peptide having adjuvant properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |